Aktiesnakken — November 2010
-
increase i cash! på 413 mill
-
r&d er faldet med 33%
-
lytter lige
-
tænkte nok det var sådan noget. tak jobo
-
ny guidance 2010
-
nu med arzerra
-
q4 royalty=q3 royalty
-
så arzerra = 55 mill
-
så news flows
-
han siger man skal følge udviklingen i forsøg på clinical trials
-
så er der q&a
-
Ubs- Jillian
-
key driver for the stock i 2011 og 2012
-
fabrikken....har i fået bud?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind